

# David T Dexter

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6211811/david-t-dexter-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35  
papers

3,737  
citations

25  
h-index

39  
g-index

39  
ext. papers

4,235  
ext. citations

6.2  
avg, IF

5.25  
L-index

#	Paper	IF	Citations
35	Data Sharing Goals for Nonprofit Funders of Clinical Trials. <i>Journal of Participatory Medicine</i> , <b>2021</b> , 13, e23011	1.4	0
34	Iron and inflammation: in vivo and post-mortem studies in Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2021</b> , 128, 15-25	4.3	9
33	Is Chelation Therapy a Potential Treatment for Parkinson's Disease?. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
32	Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease. <i>Archives of Toxicology</i> , <b>2020</b> , 94, 813-831	5.8	4
31	DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 1120-1141	6.4	7
30	L-DOPA functionalized, multi-branched gold nanoparticles as brain-targeted nano-vehicles. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2019</b> , 15, 1-11	6	40
29	The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease. <i>Journal of Neurochemistry</i> , <b>2019</b> , 148, 136-156	6	30
28	Iron as a therapeutic target for Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 568-574	7	65
27	Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. <i>Neuroscience Letters</i> , <b>2018</b> , 666, 48-57	3.3	53
26	The S100A4 Protein Signals through the ErbB4 Receptor to Promote Neuronal Survival. <i>Theranostics</i> , <b>2018</b> , 8, 3977-3990	12.1	25
25	Silver nanoparticles reduce brain inflammation and related neurotoxicity through induction of HS-synthesizing enzymes. <i>Scientific Reports</i> , <b>2017</b> , 7, 42871	4.9	75
24	Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 1398	4.9	178
23	Multibranch Gold Nanoparticles with Intrinsic LAT-1 Targeting Capabilities for Selective Photothermal Therapy of Breast Cancer. <i>ACS Applied Materials &amp; Interfaces</i> , <b>2017</b> , 9, 39259-39270	9.5	59
22	Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate. <i>Neuroscience Letters</i> , <b>2016</b> , 614, 16-23	3.3	13
21	High resolution and dynamic imaging of biopersistence and bioreactivity of extra and intracellular MWNTs exposed to microglial cells. <i>Biomaterials</i> , <b>2015</b> , 70, 57-70	15.6	27
20	Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson's disease. <i>Molecular Neurodegeneration</i> , <b>2015</b> , 10, 47	19	36
19	Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors. <i>British Journal of Pharmacology</i> , <b>2015</b> , 172, 4200-15	8.6	37

18	Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001854	11.6	76
17	Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease. <i>Neurobiology of Disease</i> , <b>2015</b> , 74, 392-405	7.5	57
16	Neurodegenerative diseases and therapeutic strategies using iron chelators. <i>Journal of Trace Elements in Medicine and Biology</i> , <b>2015</b> , 31, 267-73	4.1	86
15	Electron Microscopic Characterization of Functionalized Multi-Walled Carbon Nanotubes and Their Interactions with the Blood Brain Barrier. <i>Microscopy and Microanalysis</i> , <b>2014</b> , 20, 1744-1745	0.5	
14	Parkinson disease: from pathology to molecular disease mechanisms. <i>Free Radical Biology and Medicine</i> , <b>2013</b> , 62, 132-144	7.8	417
13	Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. <i>Journal of Neural Transmission</i> , <b>2011</b> , 118, 223-31	4.3	99
12	Brain iron metabolism and its perturbation in neurological diseases. <i>Monatshefte Für Chemie</i> , <b>2011</b> , 142, 341-355	1.4	10
11	Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson's disease. <i>Journal of the American College of Nutrition</i> , <b>2007</b> , 26, 341-9	3.5	58
10	Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition. <i>Journal of Neurochemistry</i> , <b>2007</b> , 100, 678-92	6	48
9	Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. <i>Free Radical Research</i> , <b>2005</b> , 39, 1119-25 <sup>4</sup>		317
8	Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. <i>Journal of Neuroinflammation</i> , <b>2005</b> , 2, 14	10.1	254
7	Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. <i>NeuroReport</i> , <b>2003</b> , 14, 47-50	1.7	56
6	Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. <i>NeuroReport</i> , <b>2001</b> , 12, 3871-5	1.7	159
5	Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. <i>Movement Disorders</i> , <b>2001</b> , 16, 424-34	7	70
4	Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat. <i>Biochemical Pharmacology</i> , <b>1999</b> , 58, 151-5 <sup>6</sup>		21
3	Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism. <i>Biochemical Pharmacology</i> , <b>1995</b> , 49, 1821-6	6	61
2	Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. <i>Movement Disorders</i> , <b>1994</b> , 9, 92-7	7	367
1	Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. <i>Annals of Neurology</i> , <b>1994</b> , 36, 348-55	9.4	918

